AU2017366901B2 - Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases - Google Patents
Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases Download PDFInfo
- Publication number
- AU2017366901B2 AU2017366901B2 AU2017366901A AU2017366901A AU2017366901B2 AU 2017366901 B2 AU2017366901 B2 AU 2017366901B2 AU 2017366901 A AU2017366901 A AU 2017366901A AU 2017366901 A AU2017366901 A AU 2017366901A AU 2017366901 B2 AU2017366901 B2 AU 2017366901B2
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- pyrazole
- thiazol
- carboxylic acid
- fluorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428271P | 2016-11-30 | 2016-11-30 | |
| US62/428,271 | 2016-11-30 | ||
| PCT/US2017/063774 WO2018102453A1 (en) | 2016-11-30 | 2017-11-29 | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017366901A1 AU2017366901A1 (en) | 2019-07-11 |
| AU2017366901B2 true AU2017366901B2 (en) | 2022-09-29 |
Family
ID=62241871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017366901A Active AU2017366901B2 (en) | 2016-11-30 | 2017-11-29 | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11325903B2 (enExample) |
| EP (1) | EP3548482A4 (enExample) |
| JP (1) | JP7373992B2 (enExample) |
| CN (2) | CN118930533A (enExample) |
| AU (1) | AU2017366901B2 (enExample) |
| BR (1) | BR112019011044A2 (enExample) |
| CA (1) | CA3081983A1 (enExample) |
| IL (1) | IL266930B2 (enExample) |
| MX (1) | MX2019006299A (enExample) |
| NZ (1) | NZ754827A (enExample) |
| WO (1) | WO2018102453A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3458445B1 (en) | 2016-05-18 | 2021-02-17 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| AU2017366901B2 (en) * | 2016-11-30 | 2022-09-29 | Bantam Pharmaceutical, Llc | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases |
| BR112019011035A2 (pt) * | 2016-11-30 | 2019-10-15 | Bantam Pharmaceutical Llc | métodos de uso de compostos pirazol e pirazol substituído e para o tratamento de doenças hiperproliferativas |
| EP3710439B1 (en) | 2017-11-15 | 2023-02-15 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| US10647715B2 (en) | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| EP3790551A4 (en) | 2018-05-07 | 2022-03-09 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| WO2019236966A2 (en) | 2018-06-07 | 2019-12-12 | Bantam Pharmaceutical, Llc | Methods of treatment of cancer with substituted pyrrole and pyrazole compounds and diagnosis of cancers susceptible to treatment with substituted pyrrole and pyrazole compounds |
| EP3849536A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| EP3849538A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| ES3004338T3 (en) | 2018-09-10 | 2025-03-12 | Mirati Therapeutics Inc | Combination therapies |
| WO2020118066A1 (en) | 2018-12-05 | 2020-06-11 | Mirati Therapeutics, Inc. | Combination therapies |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| CA3142196A1 (en) | 2019-05-31 | 2020-12-03 | Bantam Pharmaceutical, Llc | Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative |
| EP3976605B1 (en) | 2019-05-31 | 2025-08-20 | Bantam Pharmaceutical, LLC | Methods for making thiazolylpyrazole carboxylic acids and intermediates therefor |
| JP7622043B2 (ja) | 2019-08-29 | 2025-01-27 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｄ阻害剤 |
| CN114761012B (zh) | 2019-09-24 | 2025-03-21 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| IL294048A (en) | 2019-12-20 | 2022-08-01 | Mirati Therapeutics Inc | sos1 inhibitors |
| US20230212164A1 (en) * | 2020-06-02 | 2023-07-06 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| KR20230137286A (ko) | 2020-09-11 | 2023-10-04 | 미라티 테라퓨틱스, 인크. | Kras g12c 억제제의 결정 형태 |
| EP4262807A4 (en) | 2020-12-15 | 2025-04-23 | Mirati Therapeutics, Inc. | Azachinazoline pan-KRAS inhibitors |
| US11999753B2 (en) | 2020-12-16 | 2024-06-04 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-KRas inhibitors |
| KR20240128852A (ko) | 2021-12-01 | 2024-08-27 | 베링거 인겔하임 인터내셔날 게엠베하 | 암 치료를 위한 고리형 2-아미노-3-시아노 티오펜 및 유도체 |
| JP2024543976A (ja) * | 2021-12-01 | 2024-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌の処置のための環化２－アミノ－３－シアノチオフェン及び誘導体 |
| CN116678810A (zh) * | 2022-02-23 | 2023-09-01 | 武汉市鼎华双雄生物科技有限责任公司 | 细胞增殖免疫荧光检测试剂盒及其应用 |
| CN117003651B (zh) * | 2023-09-28 | 2024-01-02 | 广东嘉博制药有限公司 | 一种l-肾上腺素的制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004089303A2 (en) * | 2003-04-03 | 2004-10-21 | Merck & Co., Inc. | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| WO2016196644A1 (en) * | 2015-06-01 | 2016-12-08 | Bantam Pharmaceutical, Llc | Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1301968B1 (it) | 1998-07-30 | 2000-07-20 | Zambon Spa | Derivati di eritromicina ad attivita' antibiotica |
| ES2208227T3 (es) | 1999-12-03 | 2004-06-16 | Pfizer Products Inc. | Compuestos de heteroarilfenilpirazol como agentes antiinflamatorios/analgesicos. |
| EP1513534A2 (en) | 2002-04-04 | 2005-03-16 | Cv Therapeutics, Inc. | Compounds for increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis |
| JP2006523701A (ja) | 2003-04-18 | 2006-10-19 | メルク エンド カムパニー インコーポレーテッド | ナトリウムチャネルブロッカーとしてのビアリール置換チアゾール、オキサゾール、およびイミダゾール |
| WO2007138110A2 (en) | 2006-06-01 | 2007-12-06 | Devgen N.V. | Compounds that interact with ion channels, in particular with ion channels from the kv family |
| WO2008121861A2 (en) | 2007-03-28 | 2008-10-09 | Xenon Pharmaceuticals Inc. | Pyrazole and pyrrole compounds useful in treating iron disorders |
| MX2010001462A (es) | 2007-08-27 | 2010-03-01 | Basf Se | Compuestos de pirazol para controlar plagas de invertebrados. |
| CN102056907B (zh) | 2008-04-04 | 2014-12-31 | 武田药品工业株式会社 | 杂环衍生物及其用途 |
| CA2722733C (en) | 2008-04-28 | 2016-02-23 | Kyorin Pharmaceutical Co., Ltd. | Cyclopentylacrylamide derivative |
| WO2014066304A1 (en) | 2012-10-22 | 2014-05-01 | Egenix, Inc. | Compositions and methods for treating or preventing diseases or disorders associated with misregulated eif4e |
| CA2943659C (en) * | 2014-03-27 | 2023-04-25 | Merck Patent Gmbh | Pyridyl piperidines |
| WO2016169886A1 (en) | 2015-04-24 | 2016-10-27 | Syngenta Crop Protection Ag | Pesticidally active polycyclic derivatives with sulfur substituted five-membered ring heterocyles |
| BR112019011035A2 (pt) * | 2016-11-30 | 2019-10-15 | Bantam Pharmaceutical Llc | métodos de uso de compostos pirazol e pirazol substituído e para o tratamento de doenças hiperproliferativas |
| AU2017366901B2 (en) * | 2016-11-30 | 2022-09-29 | Bantam Pharmaceutical, Llc | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases |
| CA3142196A1 (en) * | 2019-05-31 | 2020-12-03 | Bantam Pharmaceutical, Llc | Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative |
-
2017
- 2017-11-29 AU AU2017366901A patent/AU2017366901B2/en active Active
- 2017-11-29 CN CN202410345199.5A patent/CN118930533A/zh active Pending
- 2017-11-29 JP JP2019528861A patent/JP7373992B2/ja active Active
- 2017-11-29 CA CA3081983A patent/CA3081983A1/en active Pending
- 2017-11-29 US US16/465,136 patent/US11325903B2/en active Active
- 2017-11-29 IL IL266930A patent/IL266930B2/en unknown
- 2017-11-29 MX MX2019006299A patent/MX2019006299A/es unknown
- 2017-11-29 NZ NZ754827A patent/NZ754827A/en unknown
- 2017-11-29 WO PCT/US2017/063774 patent/WO2018102453A1/en not_active Ceased
- 2017-11-29 CN CN201780084999.4A patent/CN110603254B/zh active Active
- 2017-11-29 BR BR112019011044-5A patent/BR112019011044A2/pt active Search and Examination
- 2017-11-29 EP EP17876486.6A patent/EP3548482A4/en active Pending
-
2022
- 2022-05-10 US US17/741,153 patent/US20230076820A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004089303A2 (en) * | 2003-04-03 | 2004-10-21 | Merck & Co., Inc. | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| WO2016196644A1 (en) * | 2015-06-01 | 2016-12-08 | Bantam Pharmaceutical, Llc | Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230076820A1 (en) | 2023-03-09 |
| NZ754827A (en) | 2025-10-31 |
| RU2019120233A3 (enExample) | 2021-03-11 |
| EP3548482A1 (en) | 2019-10-09 |
| US20190345152A1 (en) | 2019-11-14 |
| WO2018102453A1 (en) | 2018-06-07 |
| BR112019011044A2 (pt) | 2019-10-08 |
| IL266930B2 (en) | 2025-09-01 |
| IL266930A (en) | 2019-07-31 |
| JP7373992B2 (ja) | 2023-11-06 |
| MX2019006299A (es) | 2019-11-12 |
| EP3548482A4 (en) | 2020-08-19 |
| IL266930B1 (en) | 2025-05-01 |
| CN110603254B (zh) | 2024-04-12 |
| US11325903B2 (en) | 2022-05-10 |
| CN118930533A (zh) | 2024-11-12 |
| RU2019120233A (ru) | 2021-01-11 |
| CN110603254A (zh) | 2019-12-20 |
| CA3081983A1 (en) | 2018-06-07 |
| JP2019536785A (ja) | 2019-12-19 |
| AU2017366901A1 (en) | 2019-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017366901B2 (en) | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases | |
| US12150934B2 (en) | Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases | |
| US9255089B2 (en) | Benzimidazolone derivatives as bromodomain inhibitors | |
| KR102680164B1 (ko) | Rock 억제제로서의 페닐아세트아미드 | |
| AU2019246753A1 (en) | Novel compounds and compositions for inhibition of FASN | |
| RU2559895C2 (ru) | Азотосодержащие производные гетероарилов | |
| CA2932169A1 (en) | Substituted 1h-pyrrolo[2,3-b]pyridine and 1h-pyrazolo[3,4-b]pyridine derivatives as salt inducible kinase 2 (sik2) inhibitors | |
| KR20150112953A (ko) | 테트라하이드로- 및 디하이드로-이소퀴놀린 prmt5 억제제 및 이의 용도 | |
| WO2023224998A1 (en) | Inhibitors of parg | |
| CA3021185C (en) | Fused heterocyclic compound | |
| JP2018534276A (ja) | 癌治療及びエピジェネティクスのための化合物 | |
| KR20230043885A (ko) | 트리시클릭 헤테로사이클 | |
| KR20250012101A (ko) | Parg의 억제제 | |
| JP2019001715A (ja) | 三環性化合物 | |
| AU2022411461A1 (en) | Pyrimidine or pyridine derivative and medicinal use thereof | |
| Fu et al. | Structure-based drug design, synthesis, and biological evaluation of novel 1, 3, 5-triazine or pyrimidine derivatives containing benzoyl hydrazine moiety as PI3Kα selective inhibitors | |
| RU2787994C2 (ru) | Замещенные соединения пиразола и способы их применения для лечения гиперпролиферативных заболеваний | |
| CN120398829A (zh) | 2-胺基取代氮杂芳环类化合物及其药物组合物和应用 | |
| CN104003990A (zh) | 杂环胺类Hedgehog信号通路抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |